Caroline Seymour | Authors


Improved Outcomes With Trastuzumab Deruxtecan is Associated With HER2 Expression Levels in HER2+ mCRC

September 21, 2021

In patients with HER2-positive, metastatic colorectal cancer, fam-trastuzumab deruxtecan-nxki led to improved responses in patients with higher HER2 expression at baseline, whereas responses were seen irrespective of RAS- and PIK3CA mutation status and blood tumor mutational burden levels.

Notable Activity in Recurrent/Metastatic Cervical Cancer Seen With Tisotumab Vedotin Plus Frontline Carboplatin and Second-/Third-Line Pembrolizumab

September 19, 2021

Tisotumab vedotin elicited significant responses without prohibitive toxicity in combination with carboplatin as frontline therapy, as well as in combination with pembrolizumab as second- or third-line therapy in patients with recurrent or metastatic cervical cancer.

Mobocertinib Global Maximum-Tolerated Dose is Found Tolerable in Japanese Patients With NSCLC

September 16, 2021

Mobocertinib displayed a manageable safety profile across 40-mg, 120-mg, and 160-mg dose cohorts, leading to the determination of 160 mg as the maximum tolerated dose and recommended phase 2 dose for further study in Japanese patients with non–small cell lung cancer.